Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Proshares Trust (ZBIO) Preferred Stock Liabilities (2023)

Historic Preferred Stock Liabilities for Zenas BioPharma (ZBIO) over the last 1 years, with Q4 2023 value amounting to $250.1 million.

  • Zenas BioPharma's Preferred Stock Liabilities changed N/A to $250.1 million in Q4 2023 from the same period last year, while for Dec 2023 it was $250.1 million, marking a year-over-year change of. This contributed to the annual value of $250.1 million for FY2023, which is N/A changed from last year.
  • Per Zenas BioPharma's latest filing, its Preferred Stock Liabilities stood at $250.1 million for Q4 2023.
  • In the past 5 years, Zenas BioPharma's Preferred Stock Liabilities registered a high of $250.1 million during Q4 2023, and its lowest value of $193.3 million during Q3 2023.